Fluoxetine-induced apoptosis in hepatocellular carcinoma cells

Anticancer Research

Volumn 33, Issue 9, 2013, Pages 3691-3698

  Mun, A Reum ^a   Lee, Sei Jin ^b   Kim, Gi Beum ^a   Kang, Hyung Sub ^a   Kim, Jin Shang ^a   Kim, Shang Jin ^a  

^a Chonbuk National University   (South Korea)

^b Korea Basic Science Institute (KBSI)   (South Korea)

Author keywords

Apoptosis; Fluoxetine; Hep3B cells; Hepatocellular carcinoma; Mitogen activated protein kinase

Indexed keywords

ACETYLCYSTEINE; ETHYLENE GLYCOL 1,2 BIS(2 AMINOPHENYL) ETHER N,N,N',N' TETRAACETIC ACID; FLUOXETINE; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE 3; MITOGEN ACTIVATED PROTEIN KINASE P38; REACTIVE OXYGEN METABOLITE; STRESS ACTIVATED PROTEIN KINASE;

ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; CARCINOMA CELL; CELL VIABILITY; CONTROLLED STUDY; ENZYME ACTIVATION; HUMAN; HUMAN CELL; LIVER CELL CARCINOMA; MEMBRANE DEPOLARIZATION; MITOCHONDRIAL MEMBRANE; MITOCHONDRIAL MEMBRANE POTENTIAL; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION;

APOPTOSIS; FLUOXETINE; HEP3B CELLS; HEPATOCELLULAR CARCINOMA; MITOGEN-ACTIVATED PROTEIN KINASE;

APOPTOSIS; CARCINOMA, HEPATOCELLULAR; CELL LINE, TUMOR; FLUOXETINE; HUMANS; LIVER NEOPLASMS; MATRIX METALLOPROTEINASES; MITOGEN-ACTIVATED PROTEIN KINASES; REACTIVE OXYGEN SPECIES; SEROTONIN UPTAKE INHIBITORS;

EID: 84884995147     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (33)

1. Llovet JM and Bruix J: Novel advancements in the management of hepatocellular carcinoma in 2008. J Hepatol 48: S20-S37, 2008.
2. Bruix J and Sherman M: American Association for the Study of Liver Diseases. Management of hepatocellular carcinoma: an update. Hepatology 53: 1020-1022, 2011.
3. Jia WD, Sun HC, Zhang JB, Xu Y, Qian YB, Pang JZ, Wang L, Qin LX, Liu YK and Tang ZY: A novel peptide that selectively binds highly metastatic hepatocellular carcinoma cell surface is related to invasion and metastasis. Cancer Lett 247: 234-242, 2007.
4. Razavi D, Allilaire JF, Smith M, Salimpour A, Verra M, Desclaux B, Saltel P, Piollet I, Gauvain-Piquard A, Trichard C, Cordier B, Fresco R, Guillibert E, Sechter D, Orth JP, Bouhassira M, Mesters P and Blin P: The effect of fluoxetine on anxiety and depression symptoms in cancer patients. Acta Psychiatr Scand 94: 205-210,1996.
5. Verdu B, Decosterd I, Buclin T, Stiefel F and Berney A: Antidepressants for the treatment of chronic pain. Drugs 68: 2611-2632, 2008.
6. Stepulak A, Rzeski W, Sifringer M, Brocke K, Gratopp A, Kupisz K, Turski L and Ikonomidou C: fluoxetine inhibits the extracellular signal regulated kinase pathway and suppresses growth of cancer cells. Cancer Biol Thera 7: 1685-1693, 2008.
7. Krishnan A, Hariharan R, Nair SA and Pillai MR: Fluoxetine mediates G0/G1 arrest by inducing functional inhibition of cyclin dependent kinase subunit (CKS)1. Biochem Pharmacol 75: 1924-1934, 2008.
8. Navari RM, Brenner MC and Wilson MN: Treatment of depressive symptoms in patients with early stage breast cancer undergoing adjuvant therapy. Breast Cancer Res Treat 112: 197-201, 2008.
9. Cheer SM and Goa KL: Fluoxetine. A review of its therapeutic potential in the treatment of depression with physical illness. Drugs 61: 81-110, 2001.
10. Peer D, Dekel Y, Melikhov D and Margalit R: Fluoxetine inhibits multidrug resistance extrusion pumps and enhances responses to chemotherapy in syngeneic and in human xenograft mouse tumor models. Cancer Res 64: 7562-7569, 2004.
11. Zhou T, Duan J, Wang Y, Chen X, Zhou G, Wang R, Fu L and Xu F: Fluoxetine synergises with anticancer drugs to overcome multidrug resistance in breast cancer cells. Tumour Biol 33: 1299-1306, 2012.
12. Lee CS, Kim YJ, Jang ER, Kim WY and Myung SC: Fluoxetine induces apoptosis in ovarian carcinoma cell line OVCAR-3 through reactive oxygen species-dependent activation of Nuclear Factor-kB. J Basic Clin Pharmacol Toxicol 106: 446-453, 2009.
13. Kannen V, Marini T, Turatti A, Carvalho MC, Brandao ML, Jabor VA, Bonato PS, Ferreira FR, Zanette DL, Silva WA Jr. and Garcia SB: Fluoxetine induces preventive and complex effects against colon cancer development in epithelial and stromal areas in rats. Toxicol Lett 204: 134-140, 2011.
14. Xu W, Tamim H, Shapiro S, Stang MR and Collet JP: Use of antidepressants and risk of colorectal cancer: A nested case-control study. Lancet Oncol 7: 301-308. 2006.
15. Szilagyi G, Simon L, Koska P, Telek G and Nagy Z: Visualization of mitochondrial membrane potential and reactive oxygen species via double staining. Neurosci Lett 399: 206-209, 2006.
16. Buttke TM and Sandstrom PA: Oxidative stress as a mediator of apoptosis. Immunol 15: 7-10, 1994.
17. Bolo NR, Hode Y, Nedelec JF, Laine E, Wagner G and Macher JP: Brain pharmacokinetics and tissue distribution in vivo of fluvoxamine and fluoxetine by fluorine magnetic resonance spectroscopy. Neuropsychopharmacology 23: 428-438, 2000.
18. Stoll AL, Pope HG JR and McElroy SL: High-dose fluoxetine: Safety and efficacy in 27 cases. J Clin Psychopharmacol 11: 225-226, 1991.
19. Barbey JT and Roose SP: SSRI safety in overdose. J Clin Psychiatry 59: 42-48, 1998.
20. Brunelle JK and Chandel NS: Oxygen deprivation induced cell death: An update. Apoptosis 7: 475-482, 2002.
21. Ricci JE, Gottlieb RA and Green DR: Caspase-mediated loss of mitochondrial function and generation of reactive oxygen species during apoptosis. J Cell Biol 160: 65-75, 2003.
22. Takahashi K and Loo G: Disruption of mitochondria during tocotrienol-induced apoptosisin MDA-MB-231 human breast cancer cells. Biochem Pharmacol 67: 315-324, 2004.
23. Cardin R, D'Errico A, Fiorentino M, Cecchetto A, Naccarato R and Farinati F: Hepatocyte proliferation and apoptosis in relation to oxidative damage in alcohol-related liver disease. Alcohol Alcohol 37: 43-48, 2002.
24. Torres M and Forman HJ: Redox signaling and the MAP kinase pathways. BioFactors 17: 287-296, 2003.
25. McCubrey JA, Lahair MM and Franklin RA: Reactive oxygen species induced activation of the MAP kinase signaling pathways. Antioxid. Redox Signal 8: 1775-1789, 2006.
26. Yoon S and Seger R: The extracellular signal-regulated kinase: Multiple substrates regulate diverse cellular functions. Growth Factors 24: 21-44, 2006.
27. Junttila MR, Li SP and Westermarck J: Phosphatase-mediated crosstalk between MAPK signaling pathways in the regulation of cell survival. FASEB J 22: 954-965, 2008.
28. Chang HL, Wu YC, Su JH, Yeh YT and Yuan SS: Protoapigenone, a novel flavonoid, induces apoptosis in human prostate cancer cells through activation of p38 mitogen-activated protein kinase and c-Jun NH2-terminal kinase 1/2. J Pharmacol Exp Ther 325: 841-849, 2008.
29. Lee HJ, Wang CJ, Kuo HC, Chou FP, Jean LF and Tseng TH: Induction apoptosis of luteolin in human hepatoma HepG2 cells involving mitochondria translocation of BAX/BAK and activation of JNK. Toxicol Appl Pharmacol 203: 124-131, 2005.
30. Schaeffer HJ and Weber MJ: Mitogen-activated protein kinases: Specific messages from ubiquitous messengers. Mol Cell Biol 19: 2435-2444, 1999.
31. Feissner RF, Skalska J, Gaum WE and Sheu SS: Crosstalk signaling between mitochondrial Ca2+ and ROS. Front Biosci 14: 1197-1218, 2009.
32. Kowaltowski AJ, Castilho RF and Vercesi AE: Mitochondrial permeability transition and oxidative stress. FEBS Lett 495: 12-15, 2001.
33. Kowaltowski AJ, Naia-da-Silva ES, Castilho RF and Vercesi AE: Ca2+-stimulated mitochondrial reactive oxygen species generation and permeability transition are inhibited by dibucaine or Mg2+ . Arch Biochem Biophys 359: 77-81, 1998.